The Pharmacist’s Role in SARS-CoV-2 Diagnostic Testing

Abstract The World Health Organization (WHO) has declared novel coronavirus disease 2019 (COVID-19) a global pandemic. A key component in stopping the spread of SARS-CoV2 is widespread testing, however, the United States (U.S.) continues to lag behind in available testing. Currently, several SARS-CoV-2 diagnostic tests are classified as waived tests under the Clinical Laboratory Amendments (CLIA) unlocking the opportunity for pharmacy-based laboratories to process tests. Furthermore, the U.S. Department of Health and Human Services (HHS) granted pharmacists the authority to order and administer tests for SARS-CoV-2. Even with this authority, it is uncertain how community-based pharmacists will implement SARS-CoV-2 testing in practice. This paper will provide a framework for pharmacist diagnostic testing for SARS-CoV-2 including a review of the currently available CLIA-waived tests, best practices for testing and a framework with testing models and potential payment opportunities. Pharmacists are the most accessible healthcare provider and have the knowledge and skills to assume a key role in increasing SARS-CoV-2 testing in the U.S.